GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (OTCPK:SOLTF) » Definitions » EV-to-EBITDA

Nxera Pharma Co (Nxera Pharma Co) EV-to-EBITDA : -26.41 (As of Apr. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Nxera Pharma Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Nxera Pharma Co's enterprise value is $1,030.48 Mil. Nxera Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-39.02 Mil. Therefore, Nxera Pharma Co's EV-to-EBITDA for today is -26.41.

The historical rank and industry rank for Nxera Pharma Co's EV-to-EBITDA or its related term are showing as below:

SOLTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -522.25   Med: 29.62   Max: 593.4
Current: -27.76

During the past 13 years, the highest EV-to-EBITDA of Nxera Pharma Co was 593.40. The lowest was -522.25. And the median was 29.62.

SOLTF's EV-to-EBITDA is ranked worse than
100% of 473 companies
in the Biotechnology industry
Industry Median: 9.22 vs SOLTF: -27.76

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Nxera Pharma Co's stock price is $9.72. Nxera Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.605. Therefore, Nxera Pharma Co's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Nxera Pharma Co EV-to-EBITDA Historical Data

The historical data trend for Nxera Pharma Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co EV-to-EBITDA Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.14 34.28 22.57 43.51 -26.58

Nxera Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.51 39.12 23.48 -258.75 -26.58

Competitive Comparison of Nxera Pharma Co's EV-to-EBITDA

For the Biotechnology subindustry, Nxera Pharma Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's EV-to-EBITDA falls into.



Nxera Pharma Co EV-to-EBITDA Calculation

Nxera Pharma Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1030.478/-39.017
=-26.41

Nxera Pharma Co's current Enterprise Value is $1,030.48 Mil.
Nxera Pharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nxera Pharma Co  (OTCPK:SOLTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nxera Pharma Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.72/-0.605
=At Loss

Nxera Pharma Co's share price for today is $9.72.
Nxera Pharma Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.605.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Nxera Pharma Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (Nxera Pharma Co) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (Nxera Pharma Co) Headlines

From GuruFocus